Cargando…

JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients

The use of Natalizumab in Multiple Sclerosis (MS) can cause the reactivation of the polyomavirus JC (JCPyV); this may result in the development of progressive multifocal leukoencephalopathy (PML), a rare and usually lethal disease. JCPyV infection is highly prevalent in worldwide population, but the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agostini, Simone, Mancuso, Roberta, Costa, Andrea Saul, Caputo, Domenico, Clerici, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000901/ https://www.ncbi.nlm.nih.gov/pubmed/33809082 http://dx.doi.org/10.3390/v13030468

Ejemplares similares

Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab
por: Mancuso, Roberta, et al.
Publicado: (2022)

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab
por: Diotti, Roberta Antonia, et al.
Publicado: (2016)

JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients
por: Mancuso, Roberta, et al.
Publicado: (2012)

Human Polyomavirus JCPyV and Its Role in Progressive Multifocal Leukoencephalopathy and Oncogenesis
por: Del Valle, Luis, et al.
Publicado: (2019)

JCPyV-Induced MAPK Signaling Activates Transcription Factors during Infection
por: DuShane, Jeanne K., et al.
Publicado: (2019)

Discriminating between JCPyV and BKPyV in Urinary Virome Data Sets
por: Mormando, Rita, et al.
Publicado: (2021)

Detection of human neurotropic JCPyV DNA sequence in pediatric anaplastic xanthoastrocytoma
por: Passerini, Sara, et al.
Publicado: (2023)

Polyomavirus JCPyV infrequently detectable in adenoid cystic carcinoma of the oral cavity and the airways
por: Hämetoja, Hanna, et al.
Publicado: (2019)

The MAPK/ERK Pathway and the Role of DUSP1 in JCPyV Infection of Primary Astrocytes
por: Wilczek, Michael P., et al.
Publicado: (2021)

Specific and quantitative detection of Human polyomaviruses BKPyV and JCPyV in the healthy Pakistani population
por: Hussain, Iqra, et al.
Publicado: (2017)

Teriflunomide Inhibits JCPyV Infection and Spread in Glial Cells and Choroid Plexus Epithelial Cells
por: O’Hara, Bethany A., et al.
Publicado: (2021)

Inhibition of JCPyV infection mediated by targeted viral genome editing using CRISPR/Cas9
por: Chou, Yi-ying, et al.
Publicado: (2016)

JCPyV VP1 Mutations in Progressive Multifocal Leukoencephalopathy: Altering Tropism or Mediating Immune Evasion?
por: Lauver, Matthew D., et al.
Publicado: (2020)

Induction of Brain Tumors by the Archetype Strain of Human Neurotropic JCPyV in a Transgenic Mouse Model
por: Del Valle, Luis, et al.
Publicado: (2021)

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients
por: Schneider-Hohendorf, Tilman, et al.
Publicado: (2020)

IFNα and β Mediated JCPyV Suppression through C/EBPβ-LIP Isoform
por: May, Dana, et al.
Publicado: (2021)

JCPyV T-Antigen Activation of the Anti-Apoptotic Survivin Promoter—Its Role in the Development of Progressive Multifocal Leukoencephalopathy
por: Del Valle, Luis, et al.
Publicado: (2020)

The differential presence of human polyomaviruses, JCPyV and BKPyV, in prostate cancer and benign prostate hypertrophy tissues
por: Shen, Chenghuang, et al.
Publicado: (2021)

PI3K/AKT/mTOR Signaling Pathway Is Required for JCPyV Infection in Primary Astrocytes
por: Wilczek, Michael P., et al.
Publicado: (2021)

Human polyomavirus BKPyV and JCPyV serostatus has no impact on women´s human papillomavirus infection outcome
por: Laine, Hanna K., et al.
Publicado: (2023)

JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis
por: Ciardi, Maria Rosa, et al.
Publicado: (2020)

MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression
por: Mancuso, Roberta, et al.
Publicado: (2015)

Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing- Remitting Multiple Sclerosis
por: Mancuso, Roberta, et al.
Publicado: (2015)

Detection Analysis and Study of Genomic Region Variability of JCPyV, BKPyV, MCPyV, HPyV6, HPyV7 and QPyV in the Urine and Plasma of HIV-1-Infected Patients
por: Passerini, Sara, et al.
Publicado: (2022)

COS-7 and SVGp12 Cellular Models to Study JCPyV Replication and MicroRNA Expression after Infection with Archetypal and Rearranged-NCCR Viral Strains
por: Prezioso, Carla, et al.
Publicado: (2022)

Co-Detection of EBV and Human Polyomavirus JCPyV in a Case of AIDS-Related Multifocal Primary Central Nervous System Diffuse Large B-Cell Lymphoma
por: Barbier, Mallory T., et al.
Publicado: (2023)

Glioblastoma in natalizumab‐treated multiple sclerosis patients
por: Sierra Morales, Fabian, et al.
Publicado: (2017)

Serum and Exosomal miR-7-1-5p and miR-223-3p as Possible Biomarkers for Parkinson’s Disease
por: Citterio, Lorenzo Agostino, et al.
Publicado: (2023)

Prevalence and viral loads of polyomaviruses BKPyV, JCPyV, MCPyV, TSPyV and NJPyV and hepatitis viruses HBV, HCV and HEV in HIV-infected patients in China
por: Zhou, Xianfeng, et al.
Publicado: (2020)

Circulatory miR-223-3p Discriminates Between Parkinson’s and Alzheimer’s Patients
por: Mancuso, Roberta, et al.
Publicado: (2019)

HLA alleles modulate EBV viral load in multiple sclerosis
por: Agostini, Simone, et al.
Publicado: (2018)

Serum miRNAs Expression and SNAP-25 Genotype in Alzheimer’s Disease
por: Agostini, Simone, et al.
Publicado: (2019)

Relation between FCGRIIB rs1050501 and HSV-1 specific IgG antibodies in Alzheimer’s disease
por: Costa, Andrea Saul, et al.
Publicado: (2020)

miR-23a-3p and miR-181a-5p modulate SNAP-25 expression
por: Agostini, Simone, et al.
Publicado: (2023)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

HSV-1-Specific IgG(3) Titers Correlate with Brain Cortical Thinning in Individuals with Mild Cognitive Impairment and Alzheimer’s Disease
por: Mancuso, Roberta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g34qi03ub3uu546oqi4vc9sb4d